中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.021 seconds)

    R-hydroxynefazodone
    1.
    发明申请
    R-hydroxynefazodone 失效
    R-羟基吗唑酮

    公开(公告)号：US20020052382A1

    公开(公告)日：2002-05-02

    申请号：US09988935

    申请日：2001-11-19

    Applicant: Sepracor Inc.

    Inventor： Timothy J. Barberich ,  Paul D. Rubin ,  William E. Yelle

    IPC: A61K031/496

    CPC classification number: A61K31/496 ,  C07D249/12

    Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.

    Abstract translation: 奈法唑酮的羟基代谢物的R-异构体R-羟基吗啡酮是抑制剂的有效治疗剂，其不会引起与奈法唑酮相关的不良反应。 R-羟基吗唑酮也可用于治疗偏头痛，恐慌症，创伤后应激障碍和睡眠障碍。

    Compositions for treating apnea and related disorders containing optically pure R(+) ondansetron
    2.
    发明申请
    Compositions for treating apnea and related disorders containing optically pure R(+) ondansetron 审中-公开
    用于治疗包含光学纯的R（+）昂丹司琼的呼吸暂停和相关病症的组合物

    公开(公告)号：US20040058973A1

    公开(公告)日：2004-03-25

    申请号：US10665430

    申请日：2003-09-22

    Applicant: Sepracor Inc.

    Inventor： Paul D. Rubin ,  Timothy J. Barberich

    IPC: A61K031/4178

    CPC classification number: A61K31/415 ,  A61K31/4178 ,  A61K31/00 ,  A61K2300/00

    Abstract: Methods for the treatment, management, or prevention of apnea and apnea disorders, or symptoms thereof, using a therapeutically effective amount of substantially optically pure R(null) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(null) stereoisomer

    Abstract translation: 使用治疗有效量的基本上不含其S（ - ）立体异构体的基本上光学上纯的R（+）昂丹司琼或其药学上可接受的盐来治疗，管理或预防呼吸暂停和呼吸暂停障碍或其症状的方法

    R-lansoprazole compositions and methods
    4.
    发明申请
    R-lansoprazole compositions and methods 审中-公开
    R-兰索拉唑组合物和方法

    公开(公告)号：US20030008903A1

    公开(公告)日：2003-01-09

    申请号：US10216962

    申请日：2002-08-12

    Applicant: Sepracor Inc.

    Inventor： Timothy J. Barberich ,  William E. Yelle ,  Paul D. Rubin

    IPC: A61K031/4439

    CPC classification number: A61K31/4439

    Abstract: Methods and compositions are disclosed utilizing optically pure (null) lansoprazole for the treatment of S ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (null) isomer is also useful for the treatment of gastroesophageal reflux. (null) Lansoprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

    Abstract translation: 使用光学纯的（+）兰索拉唑用于治疗人类S溃疡的方法和组合物，同时显着减少与兰索拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的（+）异构体也可用于治疗胃食管反流。 （+）兰索拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

    Methods for treating apnea, apnea disorders, and other disorders using optically pure (-) norcisapride
    7.
    发明申请
    Methods for treating apnea, apnea disorders, and other disorders using optically pure (-) norcisapride 失效
    使用光学纯（ - ）诺西沙必利治疗呼吸暂停，呼吸暂停障碍和其他障碍的方法

    公开(公告)号：US20030158229A1

    公开(公告)日：2003-08-21

    申请号：US10372875

    申请日：2003-02-26

    Applicant: SEPRACOR INC.

    Inventor： Paul D. Rubin ,  Timothy J. Barberich

    IPC: A61K031/445

    CPC classification number: A61K31/445 ,  A61K31/4468

    Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (null) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (null) stereoisomer.

    Abstract translation: 使用（ - ）诺西沙必利或其药学上可接受的盐的预防，治疗或治疗呼吸暂停，呼吸暂停障碍，贪食症，肠易激综合征，尿失禁，心动过缓，缓慢性心律失常，晕厥，其他障碍或其症状的方法， 基本上不含（+）立体异构体。

    Compositions and methods employing R (-) fluoxetine and other active ingredients
    8.
    发明申请
    Compositions and methods employing R (-) fluoxetine and other active ingredients 审中-公开
    使用R（ - ）氟西汀和其他活性成分的组合物和方法

    公开(公告)号：US20020151543A1

    公开(公告)日：2002-10-17

    申请号：US10158886

    申请日：2002-06-03

    Applicant: Sepracor Inc.

    Inventor： Timothy J. Barberich ,  Paul D. Rubin ,  Dean A. Handley

    IPC: A61K031/5513 ,  A61K031/137

    CPC classification number: A61K31/495 ,  A61K31/445 ,  A61K31/505 ,  A61K31/55 ,  A61K2300/00

    Abstract: Pharmaceutical compositions which comprises R(null) fluoxetine and one or more other biologically active compounds are disclosed. Methods of treating or preventing a disease or disorder, especially a psychotic or psychiatric disease or disorder, using the above pharmaceutical composition or by administering a R(null) fluoxetine in combination with one or more other biologically active compounds are also disclosed. Methods of treating patients having or at risk of having AIDS or HIV infection, cancer, cardiac disorder, post-myocardial depression and posttraumatic stress disorder using optically pure R(null) fluoxetine in combination with one or more other biologically active compounds are further disclosed.

    Abstract translation: 公开了包含R（ - ）氟西汀和一种或多种其它生物活性化合物的药物组合物。 还公开了使用上述药物组合物或通过与一种或多种其它生物活性化合物组合施用R（ - ）氟西汀来治疗或预防疾病或障碍，特别是精神病或精神疾病或病症的方法。 进一步公开了使用光学纯的R（ - ）氟西汀与一种或多种其它生物活性化合物组合治疗患有AIDS或HIV感染或有风险患有癌症，心脏病，心肌后抑郁症和创伤后应激障碍的患者的方法。

    Methods for treating apnea and apnea disorders using optically pure (+) norcisapride
    9.
    发明申请
    Methods for treating apnea and apnea disorders using optically pure (+) norcisapride 失效
    使用光学纯（+）诺西沙必利治疗呼吸暂停和呼吸暂停障碍的方法

    公开(公告)号：US20020147220A1

    公开(公告)日：2002-10-10

    申请号：US10075617

    申请日：2002-02-15

    Applicant: Sepracor Inc.

    Inventor： Paul D. Rubin ,  Timothy J. Barberich

    IPC: A61K031/445

    CPC classification number: A61K31/445 ,  A61K31/4468

    Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (null) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (null) stereoisomer.

    Abstract translation: 使用（+）诺西沙必利或其药学上可接受的盐的预防，治疗或治疗呼吸暂停，呼吸暂停障碍，贪食症，肠易激综合征，尿失禁，心动过缓，缓慢性心律失常，晕厥，其他障碍或其症状的方法， 基本上不含（ - ）立体异构体。

    R-lansoprazole compositions and methods
    10.
    发明申请
    R-lansoprazole compositions and methods 审中-公开
    R-兰索拉唑组合物和方法

    公开(公告)号：US20020042433A1

    公开(公告)日：2002-04-11

    申请号：US09981108

    申请日：2001-10-17

    Applicant: SEPRACOR INC.

    Inventor： William E. Yelle ,  Timothy J. Barberich ,  Paul D. Rubin

    IPC: A61K031/4439

    CPC classification number: A61K31/4439

    Abstract: Methods and compositions are disclosed utilizing optically pure (null) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (null) isomer is also useful for the treatment of gastroesophageal reflux. (null) Lansoprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

    Abstract translation: 公开了使用光学纯的（+）兰索拉唑治疗人类溃疡的方法和组合物，同时显着减少与兰索拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的（+）异构体也可用于治疗胃食管反流。 （+）兰索拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

Patent Agency Ranking